| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1012668241 |
| P356 | DOI | 10.1186/AR3380 |
| P932 | PMC publication ID | 3239343 |
| P698 | PubMed publication ID | 21861862 |
| P5875 | ResearchGate publication ID | 51590495 |
| P2093 | author name string | Jochen Zwerina | |
| Tobias Braun | |||
| P2860 | cites work | IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines | Q24294720 |
| Discovery of a cytokine and its receptor by functional screening of the extracellular proteome | Q24310846 | ||
| The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models | Q24519770 | ||
| IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis | Q24563235 | ||
| Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis | Q24564656 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Control of RANKL gene expression | Q24619669 | ||
| T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines | Q24678115 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis | Q24792451 | ||
| IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways | Q24793443 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| LDL-receptor-related protein 6 is a receptor for Dickkopf proteins | Q28116567 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| The interleukin-1 family: 10 years of discovery | Q28243296 | ||
| Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 | Q28279735 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation | Q28505419 | ||
| Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects | Q28505493 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies | Q28570898 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis | Q77742326 | ||
| Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice | Q78124718 | ||
| High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study | Q79422602 | ||
| Dickkopf-1 is a master regulator of joint remodeling | Q79610564 | ||
| Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota | Q79770437 | ||
| Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment | Q80445625 | ||
| Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways | Q80763818 | ||
| Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis | Q83398961 | ||
| Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 | ||
| IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17 | Q84511967 | ||
| Osteoporosis in Ankylosing Spondylitis | Q84641713 | ||
| Radiographic study on the pattern of wrist joint destruction in rheumatoid arthritis | Q85059586 | ||
| Annotating genes with potential roles in the immune system: six new members of the IL-1 family | Q28679180 | ||
| Genetic regulation of osteoclast development and function | Q29617421 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| Interleukin-1 is essential for systemic inflammatory bone loss | Q33406072 | ||
| Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse | Q33646429 | ||
| Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
| Transcriptional regulation of bone and joint remodeling by NFAT | Q33998768 | ||
| Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis | Q34059280 | ||
| Interleukin-1 (IL-1) pathway | Q34093681 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| M-CSF mediates TNF-induced inflammatory osteolysis | Q34133595 | ||
| Strength of TRAF6 signalling determines osteoclastogenesis | Q34166675 | ||
| IgG1 plasmacytosis in interleukin 6 transgenic mice | Q34308376 | ||
| Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. | Q34360402 | ||
| The IL-33/ST2 pathway: therapeutic target and novel biomarker | Q34776884 | ||
| Risk of vertebral fracture in women with rheumatoid arthritis | Q35187252 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo | Q35575987 | ||
| Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology | Q35592741 | ||
| Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways | Q35632149 | ||
| TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis | Q35788463 | ||
| B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo | Q35804512 | ||
| Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors | Q35824058 | ||
| TNF-induced structural joint damage is mediated by IL-1. | Q35880188 | ||
| Cytokine patterns and pathogenicity in autoimmune diseases. | Q35939237 | ||
| Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes | Q36101730 | ||
| Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice | Q36166760 | ||
| Interleukin 6 plays a key role in the development of antigen-induced arthritis | Q36172826 | ||
| Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis | Q36371110 | ||
| A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis | Q36371158 | ||
| The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis | Q36371653 | ||
| Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice | Q36375776 | ||
| Interleukin 6 is required for the development of collagen-induced arthritis | Q36400353 | ||
| Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways | Q42494588 | ||
| Macrophage colony-stimulating factor promotes cell survival through Akt/protein kinase B. | Q42811250 | ||
| Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis | Q43146568 | ||
| Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. | Q43775920 | ||
| Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects | Q43833399 | ||
| Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin | Q43937881 | ||
| Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction | Q43945860 | ||
| IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae | Q44129538 | ||
| Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. | Q46030946 | ||
| Mast cells express IL-17A in rheumatoid arthritis synovium | Q46151437 | ||
| Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo | Q46265274 | ||
| Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system | Q46280827 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival | Q47982674 | ||
| Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. | Q48083226 | ||
| TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. | Q50335956 | ||
| Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor | Q51049420 | ||
| Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. | Q51548531 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. | Q54420652 | ||
| Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis | Q57232104 | ||
| Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis | Q57265520 | ||
| Multiple roles of M-CSF in human osteoclastogenesis | Q57533490 | ||
| NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 | Q57675122 | ||
| Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 | ||
| JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms | Q58326878 | ||
| Bone and haematopoietic defects in mice lacking c-fos | Q58326969 | ||
| T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand-Dependent and -Independent Mechanisms | Q60524745 | ||
| Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines | Q60524890 | ||
| The -Isoform of p38 MAPK Specifically Regulates Arthritic Bone Loss | Q61900817 | ||
| Pleiotropic effects of a null mutation in the c-fos proto-oncogene | Q62555352 | ||
| Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides | Q68094829 | ||
| Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production | Q68435194 | ||
| Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization | Q68632086 | ||
| Generalised bone loss in patients with early rheumatoid arthritis | Q72682386 | ||
| Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium | Q73343798 | ||
| The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis | Q73414195 | ||
| Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts | Q73441763 | ||
| High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism | Q73458527 | ||
| Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid | Q73601079 | ||
| Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines | Q74269794 | ||
| IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages | Q74412124 | ||
| Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6 | Q74488822 | ||
| Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells | Q74520565 | ||
| A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2 | Q74595874 | ||
| Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice | Q75197457 | ||
| Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium | Q77738643 | ||
| I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss | Q36402985 | ||
| Mechanisms of pathologic new bone formation. | Q36594210 | ||
| The molecular understanding of osteoclast differentiation | Q36650749 | ||
| IL-33 exacerbates antigen-induced arthritis by activating mast cells | Q36800502 | ||
| The IL-6/sIL-6R complex as a novel target for therapeutic approaches | Q36804420 | ||
| TNF-mediated inflammatory disease. | Q37045764 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation | Q37286240 | ||
| Evidence that cytokines play a role in rheumatoid arthritis | Q37316594 | ||
| M-CSF elevates c-Fos and phospho-C/EBPalpha(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification | Q37348266 | ||
| Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts | Q37418258 | ||
| A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner | Q37438928 | ||
| Osteoimmunology: crosstalk between the immune and bone systems | Q37544448 | ||
| Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion | Q37629702 | ||
| The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase | Q37647341 | ||
| TNF and bone | Q37696082 | ||
| Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis | Q37742906 | ||
| Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis | Q37767493 | ||
| Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. | Q38594831 | ||
| PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. | Q38744013 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis | Q39539886 | ||
| Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells | Q39645392 | ||
| Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. | Q39993181 | ||
| Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases | Q40184342 | ||
| Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines | Q40241909 | ||
| Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion | Q40590532 | ||
| Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis | Q40646100 | ||
| TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis | Q40666297 | ||
| Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors | Q40727130 | ||
| Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. | Q40876856 | ||
| IL-1 mediates TNF-induced osteoclastogenesis | Q40909592 | ||
| Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells | Q41373053 | ||
| Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis | Q41702676 | ||
| Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice | Q41873647 | ||
| Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts | Q41910302 | ||
| A novel T cell cytokine stimulates interleukin-6 in human osteoblastic cells | Q42474660 | ||
| P433 | issue | 4 | |
| P921 | main subject | peptide | Q172847 |
| rheumatoid arthritis | Q187255 | ||
| cytokine | Q212354 | ||
| osteoclast | Q828410 | ||
| bone resorption | Q4941581 | ||
| P304 | page(s) | 235 | |
| P577 | publication date | 2011-07-28 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis | |
| P478 | volume | 13 |
| Q36207488 | Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis |
| Q54286064 | Activation of the liver X receptor-β potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages. |
| Q42428090 | Allium cepa L. and Quercetin Inhibit RANKL/Porphyromonas gingivalis LPS-Induced Osteoclastogenesis by Downregulating NF-κB Signaling Pathway |
| Q36487325 | An HLA-DRB1-coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity |
| Q51241804 | Aryl hydrocarbon receptor suppresses the osteogenesis of mesenchymal stem cells in collagen-induced arthritic mice through the inhibition of β-catenin. |
| Q36065421 | Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. |
| Q38177181 | Autoantibody-mediated bone loss |
| Q49380410 | Bacterial modulators of bone remodeling in the periodontal pocket |
| Q38185586 | Bone and the innate immune system |
| Q38072313 | Bone research in 2012: the ups and downs of bone in health and rheumatic disease |
| Q41106264 | Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. |
| Q36820237 | C/EBPα regulates osteoclast lineage commitment |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q39361224 | Cellular and molecular pathways of structural damage in rheumatoid arthritis |
| Q33805455 | Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells |
| Q37410560 | Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation |
| Q59806580 | Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis |
| Q38193090 | Classical and Paradoxical Effects of TNF-α on Bone Homeostasis |
| Q53441152 | Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation. |
| Q34976399 | Differential arthritogenicity of Staphylococcus aureus strains isolated from biological samples. |
| Q52962027 | Double Stranded RNA-Dependent Protein Kinase is Necessary for TNF-α-Induced Osteoclast Formation In Vitro and In Vivo. |
| Q41875487 | Double-edged-sword effect of IL-1β on the osteogenesis of periodontal ligament stem cells via crosstalk between the NF-κB, MAPK and BMP/Smad signaling pathways |
| Q37472450 | Elevation of serum tumor necrosis factor α in patients with periprosthetic osteolysis: a case-control study |
| Q64245139 | Gene Expression Profiling of NFATc1-Knockdown in RAW 264.7 Cells: An Alternative Pathway for Macrophage Differentiation |
| Q36691934 | Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis |
| Q35311994 | Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss |
| Q47122664 | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis. |
| Q89697251 | Hydrogen Sulfide as Potential Regulatory Gasotransmitter in Arthritic Diseases |
| Q41890076 | IL-17 in the rheumatologist's line of sight |
| Q44812595 | IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis |
| Q36444288 | IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1). |
| Q58801220 | Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses |
| Q92832864 | Impairment of bone microstructure and upregulation of osteoclastogenic markers in spontaneously hypertensive rats |
| Q48297258 | Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis. |
| Q38218977 | Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis |
| Q38126619 | Inflammatory mediators in the pathogenesis of periodontitis |
| Q43764987 | Inhibition of P2X4 suppresses joint inflammation and damage in collagen-induced arthritis |
| Q37626939 | Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. |
| Q34289171 | Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis |
| Q90027716 | Magnolol Inhibits Osteoclast Differentiation via Suppression of RANKL Expression |
| Q92355433 | Mechanisms by which sialylated milk oligosaccharides impact bone biology in a gnotobiotic mouse model of infant undernutrition |
| Q38576851 | Mediators of inflammation and bone remodeling in rheumatic disease |
| Q36074393 | Microarray-based gene expression profiling reveals the mediators and pathways involved in the anti-arthritic activity of Celastrus-derived Celastrol |
| Q40376112 | Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats |
| Q43623184 | Moonlighting osteoclasts as undertakers of apoptotic cells |
| Q37153667 | Mucosal Langerhans Cells Promote Differentiation of Th17 Cells in a Murine Model of Periodontitis but Are Not Required for Porphyromonas gingivalis-Driven Alveolar Bone Destruction |
| Q64052666 | MyD88 and IL-1R signaling drive antibacterial immunity and osteoclast-driven bone loss during Staphylococcus aureus osteomyelitis |
| Q35617591 | Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors |
| Q38076334 | Neutrophils, IL-1β, and gout: is there a link? |
| Q38799600 | New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis |
| Q61814977 | Ninjurin1 positively regulates osteoclast development by enhancing the survival of prefusion osteoclasts |
| Q34639619 | Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways |
| Q64236844 | Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis |
| Q40560466 | Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases |
| Q92502785 | Osteostatin Inhibits Collagen-Induced Arthritis by Regulation of Immune Activation, Pro-Inflammatory Cytokines, and Osteoclastogenesis |
| Q37105605 | Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility |
| Q38004935 | Pathways for bone loss in inflammatory disease |
| Q90723642 | Proinflammatory Effects of IL-1β Combined with IL-17A Promoted Cartilage Degradation and Suppressed Genes Associated with Cartilage Matrix Synthesis In Vitro |
| Q33692037 | Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis |
| Q36246148 | RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis |
| Q33592037 | Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. |
| Q38679162 | Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114. |
| Q38102876 | Regulation of TNF-α with a focus on rheumatoid arthritis |
| Q35666187 | Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling |
| Q33711522 | Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis |
| Q26801098 | Role of Micro RNAs in the Pathogenesis of Rheumatoid Arthritis: Novel Perspectives Based on Review of the Literature |
| Q50234923 | Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis |
| Q37586474 | Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells |
| Q39307600 | Synthesis and discovery of novel pyrazole carboxamide derivatives as potential osteogenesis inducers |
| Q42623135 | T cells as key players for bone destruction in gouty arthritis? |
| Q38114069 | Targeting BCL2 family in human myeloid dendritic cells: a challenge to cure diseases with chronic inflammations associated with bone loss |
| Q47331159 | The Role of Autoantibodies in Bone Metabolism and Bone Loss |
| Q46283603 | The calcification potential of human MSCs can be enhanced by interleukin-1β in osteogenic medium. |
| Q55433496 | The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice. |
| Q51842603 | The preventive effect of ambroxol hydrochloride chitosan on postoperative intraperitoneal adhesion formation in a rat model. |
| Q36111285 | The role of RANK ligand/osteoprotegerin in rheumatoid arthritis |
| Q35213395 | Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation |
| Q36723165 | Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway |
| Q39209603 | Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. |
Search more.